title: Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
abstract: Bisphosphonates are widely used for the treatment of metastatic skeletal tumors and hypercalcemia resulting from malignant tumors. Zoledronic acid (ZOL), a third-generation bisphosphonate agent, was recently demonstrated to show synergistic antitumor activity of ZOL when combined with chemotherapy in lung cancer patients. However, whether ZOL exerts direct antitumor activity on lung cancer remains unclear. Here, we report an atypical case encountered while treating a 57-year-old woman with pulmonary adenocarcinoma and multiple metastases of the liver, left adrenal gland, and bone. The nonskeletal lesions, consisting of the primary lesion and hepatic metastasis, regressed after treatment with ZOL alone. We believe this case demonstrates a possible antitumor effect of ZOL against lung cancer.
authors.affiliation: Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
authors.forename: Saeko
authors.initials: S
authors.lastname: Nagao
authors.forename: Noboru
authors.initials: N
authors.lastname: Hattori
authors.forename: Kazunori
authors.initials: K
authors.lastname: Fujitaka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iwamoto
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Ohshimo
authors.forename: Masashi
authors.initials: M
authors.lastname: Kanehara
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Ishikawa
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Haruta
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Murai
authors.forename: Nobuoki
authors.initials: N
authors.lastname: Kohno
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009365:Neoplasm Regression, Spontaneous; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid